• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • injectable medications
Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

Posted by By MedXY 09/07/2025
Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.
Read More
  • Addressing Disparities in Post-Stroke Community Rehabilitation: Insights from the COMPASS Study
  • Harnessing Wearable Technology to Boost Cardiac Rehabilitation Adherence in CHD Patients: Insights from a Randomized Trial
  • Revolutionizing Cardiac Rehab: The Impact of Wearable Technology and Online Coaching
  • X-CircuiT versus Conventional Exercise in Home-Based Cardiac Rehabilitation: A Non-Inferiority Randomized Trial for CAD Patients
  • Risk Factors Influencing Implant Failure in Full-Arch Fixed Rehabilitation: Insights from a 7-Year Retrospective Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial COPD depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation longevity mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in